Expression and clinical significance of tyrosine phosphatase SHP2 in thyroid carcinoma

Hu,Zhong‑Qian; Ma,Rui; Zhang,Chi‑Min; Li,Jia; Li,Ling; Hu,Zhong‑Ting; Gao,Qi; Li,Wei‑Min

doi:10.3892/ol.2015.3479

Expression and clinical significance of tyrosine phosphatase SHP2 in thyroid carcinoma

Authors:
- Zhong‑Qian Hu
- Rui Ma
- Chi‑Min Zhang
- Jia Li
- Ling Li
- Zhong‑Ting Hu
- Qi Gao
- Wei‑Min Li
View Affiliations

Affiliations: Department of Ultrasound, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, Jiangsu 210009, P.R. China, Department of Cardiology, Jinling Hospital, Nanjing, Jiangsu 210002, P.R. China
Published online on: July 10, 2015 https://doi.org/10.3892/ol.2015.3479
Pages: 1507-1512

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Protein-tyrosine phosphatase SHP2 is encoded by the gene PTPN11. SHP2 is hypothesized to have a critical role in cancer, via the activation of mutations that have been detected in several types of leukaemia and in certain solid tumours, including liver, breast, gastric and cervical cancer. However, to the best of our knowledge, there have been no previous reports evaluating the significance of SHP2 expression in thyroid cancer. The present study evaluated SHP2 expression in 65 thyroid cancer specimens, 40 specimens of self‑matched adjacent peritumour tissues and 40 specimens of normal thyroid tissue, using immunohistochemical and western blot analyses with an anti-SHP2 antibody. Western blotting was also used to assess SHP2 expression in thyroid cancer cell lines (SW579, IHH‑4, FTC‑133, TPC‑1, DRO, TA‑K, and ML‑1) and Nthy‑ori3‑1 normal thyroid cells. In addition, SHP2 antisense oligonucleotides were used to block SHP2 expression in SW579 cells, and growth inhibition assays were conducted. Increased SHP2 expression was detected in the tumour tissues compared with that of the normal thyroid tissues (P<0.05). SHP2 expression was significantly correlated with poor tumour differentiation (P<0.05), late TNM stage (P<0.05) and lymph node metastasis (P<0.05), suggesting that SHP2 may represent a potential target for thyroid cancer therapy.

View Figures

View References

1	Grossmann KS, Rosário M, Birchmeier C and Birchmeier W: The tyrosine phosphatase SHP2 in development and cancer. Adv Cancer Res. 106:53–89. 2010. View Article : Google Scholar : PubMed/NCBI
2	Ferrari E, Tinti M, Costa S, et al: Identification of new substrates of the protein-tyrosine phosphatase PTP1B by Bayesian integration of proteome evidence. J Biol Chem. 286:4173–4185. 2011. View Article : Google Scholar : PubMed/NCBI
3	Araki T, Chan G, Newbigging S, et al: Noonan syndrome cardiac defects are caused by PTPN11 acting in endocardium to enhance endocardial-mesenchymal transformation. Proc Natl Acad Sci USA. 106:4736–4741. 2009. View Article : Google Scholar : PubMed/NCBI
4	Hagihara K, Zhang EE, Ke YH, et al: Shp2 acts downstream of SDF-1alpha/CXCR4 in guiding granule cell migration during cerebellar development. Dev Biol. 334:276–284. 2009. View Article : Google Scholar : PubMed/NCBI
5	Niihori T, Aoki Y, Ohashi H, et al: Functional analysis of PTPN11/SHP-2 mutants identified in Noonan syndrome and childhood leukemia. J Hum Gene. 50:192–202. 2005. View Article : Google Scholar
6	Ogata T and Yoshida R: PTPN11 mutations and genotype-phenotype correlations in Noonan and LEOPARD syndromes. Pediatr Endocrinol Rev. 2:669–674. 2005.PubMed/NCBI
7	Oh ES, Gu H, Saxton TM, et al: Regulation of early events in integrin signaling by protein tyrosine phosphatase SHP-2. Mol Cell Biol. 19:3205–3215. 1999.PubMed/NCBI
8	Bowen ME, Ayturk UM, Kurek KC, et al: SHP2 regulates chondrocyte terminal differentiation, growth plate architecture and skeletal cell fates. PLoS Genet. 10:e10043642014. View Article : Google Scholar : PubMed/NCBI
9	Hartman ZR, Schaller MD and Agazie YM: The tyrosine phosphatase SHP2 regulates focal adhesion kinase to promote EGF-induced lamellipodia persistence and cell migration. Mol Cancer Res. 11:651–664. 2013. View Article : Google Scholar : PubMed/NCBI
10	Qiu W, Wang X, Romanov V, et al: Structural insights into Noonan/LEOPARD syndrome-related mutants of protein-tyrosine phosphatase SHP2 (PTPN11). BMC Struct Biol. 14:102014. View Article : Google Scholar : PubMed/NCBI
11	Oishi K, Zhang H, Gault WJ, et al: Phosphatase-defective LEOPARD syndrome mutations in PTPN11 gene have gain-of-function effects during Drosophila development. Hum Mol Genet. 18:193–201. 2009. View Article : Google Scholar : PubMed/NCBI
12	Chan G, Kalaitzidis D, Usenko T, et al: Leukemogenic Ptpn11 causes fatal myeloproliferative disorder via cell-autonomous effects on multiple stages of hematopoiesis. Blood. 113:4414–4424. 2009. View Article : Google Scholar : PubMed/NCBI
13	Schneeberger VE, Luetteke N, Ren Y, et al: SHP2E76K mutant promotes lung tumorigenesis in transgenic mice. Carcinogenesis. 35:1717–1725. 2014. View Article : Google Scholar : PubMed/NCBI
14	Furcht CM, Muñoz Rojas AR, Nihalani D and Lazzara MJ: Diminished functional role and altered localization of SHP2 in non small cell lung cancer cells with EGFR-activating mutations. Oncogene. 32:2346–2355. 2013. View Article : Google Scholar : PubMed/NCBI
15	Sausgruber N, Coissieux MM, Britschgi A, et al: Tyrosine phosphatase SHP2 increases cell motility in triple-negative breast cancer through the activation of SRC-family kinases. Oncogene. 34:2272–2278. 2015. View Article : Google Scholar : PubMed/NCBI
16	Hu Z, Fang H, Wang X, et al: Overexpression of SHP2 tyrosine phosphatase promotes the tumorigenesis of breast carcinoma. Oncol Rep. 32:205–212. 2014.PubMed/NCBI
17	Aceto N, Sausgruber N, Brinkhaus H, et al: Tyrosine phosphatase SHP2 promotes breast cancer progression and maintains tumor-initiating cells via activation of key transcription factors and a positive feedback signaling loop. Nat Med. 18:529–537. 2012. View Article : Google Scholar : PubMed/NCBI
18	Jiang J, Jin MS, Kong F, et al: Increased expression of tyrosine phosphatase SHP-2 in Helicobacter pylori-infected gastric cancer. World J Gastroenterol. 19:575–580. 2013. View Article : Google Scholar : PubMed/NCBI
19	Dong LB, Li GQ, Tian ZH, et al: Expressions of Src homology 2 domain-containing phosphatase and its clinical significance in laryngeal carcinoma. Genet Mol Res. 12:4207–4212. 2013. View Article : Google Scholar : PubMed/NCBI
20	Wang HC, Chiang WF, Huang HH, et al: Src-homology 2 domain-containing tyrosine phosphatase 2 promotes oral cancer invasion and metastasis. BMC Cancer. 14:4422014. View Article : Google Scholar : PubMed/NCBI
21	Bard-Chapeau EA, Li S, Ding J, et al: PTPN11/SHP2 acts as a tumor suppressor in hepatocellular carcinogenesis. Cancer Cell. 19:629–639. 2011. View Article : Google Scholar : PubMed/NCBI
22	Cai P, Guo W, Yuan H, et al: Expression and clinical significance of tyrosine phosphatase SHP-2 in colon cancer. Biomed Pharmacother. 68:285–290. 2014. View Article : Google Scholar : PubMed/NCBI
23	Sharma N, Everingham S, Ramdas B, et al: SHP2 phosphatase promotes mast cell chemotaxis toward stem cell factor via enhancing activation of the Lyn/Vav/Rac signaling axis. J Immunol. 192:4859–4866. 2014. View Article : Google Scholar : PubMed/NCBI
24	Princen F, Bard E, Sheikh F, et al: Deletion of Shp2 tyrosine phosphatase in muscle leads to dilated cardiomyopathy, insulin resistance and premature death. Mol Cell Biol. 29:378–388. 2009. View Article : Google Scholar : PubMed/NCBI
25	Edwards JJ, Martinelli S, Pannone L, et al: A PTPN11 allele encoding a catalytically impaired SHP2 protein in a patient with a Noonan syndrome phenotype. Am J Med Genet A. 164A:2351–2355. 2014. View Article : Google Scholar : PubMed/NCBI
26	Müller PJ, Rigbolt KT, Paterok D, et al: Protein tyrosine phosphatase SHP2/PTPN11 mistargeting as a consequence of SH2-domain point mutations associated with Noonan Syndrome and leukemia. J Proteomics. 84:132–147. 2013. View Article : Google Scholar : PubMed/NCBI
27	Luo H, Tang C, Yang X and Zhou X: The tyrosine phosphatase SHP2: A key molecule linked both type 2 diabetes and cancers? Med Chem. 4:435–438. 2014.
28	Meng F, Zhao X and Zhang S: SHP-2 phosphatase promotes cervical cancer cell proliferation through inhibiting interferon-β production. J Obstet Gynaecol Res. 39:272–279. 2013. View Article : Google Scholar : PubMed/NCBI